Revenue scaled from $29.5B in 2024Q2 to $41.2B in 2026Q3, yet the combined ratio crossed 100% in both 2024Q4 and 2025Q4 and net income fell to $162.0M in the latest quarter, indicating thin and unstable underwriting margins.
Humana Inc. (HUM) annual income statement — 30-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Revenue | 154.19B | 129.66B | 117.81B | 106.44B | 92.92B | 83.65B | 77.19B | 64.93B | 56.94B | 53.8B | 54.41B | 54.29B | 48.5B | 41.31B | 39.13B | 36.83B | 33.87B | 30.96B | 29.05B | 25.29B | 21.42B | 14.42B | 13.1B | 12.23B | 11.26B | 10.19B | 10.6B | 10.21B | 9.87B | 8.04B | 6.79B |
| Revenue Growth % | 22.02% | 10.06% | 10.68% | 14.55% | 11.09% | 8.37% | 18.88% | 14.03% | 5.84% | -1.11% | 0.21% | 11.94% | 17.4% | 5.59% | 6.23% | 8.75% | 9.39% | 6.58% | 14.87% | 18.09% | 48.54% | 10.03% | 7.18% | 8.57% | 10.46% | -3.79% | 3.76% | 3.5% | 22.77% | 18.39% | 44.36% |
| Medical Costs & Claims | 134.12B | 110.81B | 100.66B | 88.39B | 75.69B | 69.2B | 61.5B | 53.74B | 45.75B | 43.39B | 44.9B | 44.18B | 38.17B | 32.56B | 30.94B | 28.82B | 27.09B | 24.78B | 23.71B | 20.27B | 17.42B | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Medical Cost Ratio % | 86.99% | 85.46% | 85.45% | 83.05% | 81.46% | 82.73% | 79.67% | 82.76% | 80.35% | 80.65% | 82.52% | 81.37% | 78.69% | 78.82% | 79.08% | 78.26% | 79.98% | 80.02% | 81.61% | 80.15% | 81.34% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Gross Profit | 20.06B | 18.85B | 17.15B | 18.05B | 17.23B | 14.45B | 15.69B | 11.19B | 11.19B | 7.08B | 7.77B | 7.76B | 7.97B | 6.69B | 6.13B | 5.67B | 4.76B | 4.48B | 4.17B | 3.66B | 3.17B | 0 | 0 | 12.23B | 11.26B | 10.19B | 10.6B | 10.21B | 9.87B | 8.04B | 6.79B |
| Gross Margin % | 13.01% | 14.54% | 14.55% | 16.95% | 18.54% | 17.27% | 20.33% | 17.24% | 19.65% | 13.17% | 14.28% | 14.3% | 16.44% | 16.19% | 15.65% | 15.38% | 14.06% | 14.46% | 14.34% | 14.48% | 14.8% | 0% | 0% | 100% | 100% | 100% | 100% | 100% | 100% | 100% | 100% |
| Gross Profit Growth % | - | 9.94% | -4.98% | 4.72% | 19.26% | -7.91% | 40.18% | 0.02% | 57.95% | -8.79% | 0.04% | -2.6% | 19.2% | 9.19% | 8.12% | 18.93% | 6.38% | 7.51% | 13.76% | 15.49% | - | - | -100% | 8.57% | 10.46% | -3.79% | 3.76% | 3.5% | 22.77% | 18.39% | 44.36% |
| Operating Expenses | 18.07B | 17.4B | 15.52B | 14.73B | 13.67B | 11.03B | 11.02B | 7.72B | 9.12B | 7.08B | 7.77B | 7.76B | 7.97B | 6.69B | 6.13B | 5.67B | 4.76B | 4.48B | 4.17B | 3.66B | 3.17B | 0 | 2B | 11.89B | 11.06B | 10.01B | 10.48B | 10.62B | 9.66B | 1.14B | 1.05B |
| OpEx / Revenue % | 11.72% | 13.42% | 13.17% | 13.84% | 14.71% | 13.19% | 14.27% | 11.89% | 16.01% | 13.17% | 14.28% | 14.3% | 16.44% | 16.19% | 15.65% | 15.38% | 14.06% | 14.46% | 14.34% | 14.48% | 14.8% | 0% | 15.23% | 97.25% | 98.19% | 98.2% | 98.92% | 103.96% | 97.94% | 14.14% | 15.42% |
| Depreciation & Amortization | 763M | 824M | 968M | 917M | 845M | 713M | 616M | 575M | 534M | 485M | 465M | 447M | 449M | 426M | 338M | 303M | 263M | 250.27M | 220.35M | 184.81M | 148.6M | 128.86M | 117.79M | 126.78M | 120.73M | 171.02M | 153.62M | 126.96M | 128M | 108M | 98M |
| Combined Ratio % | 98.71% | 98.88% | 98.62% | 96.88% | 96.16% | 95.91% | 93.94% | 94.66% | 96.36% | 93.82% | 96.8% | 95.68% | 95.13% | 95.01% | 94.73% | 93.64% | 94.04% | 94.48% | 95.95% | 94.63% | 96.15% | 0% | 15.23% | 97.25% | 98.19% | 98.2% | 98.92% | 103.96% | 97.94% | 14.14% | 15.42% |
| Operating Income | 1.99B | 1.45B | 1.63B | 3.32B | 3.56B | 3.42B | 4.67B | 3.47B | 2.07B | 3.33B | 1.74B | 2.35B | 2.36B | 2.06B | 2.06B | 2.34B | 2.02B | 1.71B | 1.18B | 1.36B | 825.23M | 461.03M | 439.02M | 336.21M | 203.55M | 183.08M | 113.99M | -404.84M | 203.08M | 6.9B | 5.74B |
| Operating Margin % | 1.29% | 1.12% | 1.38% | 3.12% | 3.84% | 4.09% | 6.06% | 5.34% | 3.64% | 6.18% | 3.2% | 4.32% | 4.87% | 4.99% | 5.27% | 6.36% | 5.96% | 5.52% | 4.05% | 5.37% | 3.85% | 3.2% | 3.35% | 2.75% | 1.81% | 1.8% | 1.08% | -3.96% | 2.06% | 85.86% | 84.58% |
| Operating Income Growth % | - | -10.69% | -50.99% | -6.85% | 4.24% | -26.85% | 34.7% | 67.31% | -37.64% | 91.04% | -25.82% | -0.64% | 14.6% | -0.05% | -12.03% | 16.21% | 18.12% | 45.18% | -13.4% | 64.58% | 79% | 5.01% | 30.58% | 65.18% | 11.18% | 60.61% | 128.16% | -299.35% | -97.06% | 20.19% | 39.34% |
| EBITDA | 2.75B | 2.28B | 2.6B | 4.24B | 4.41B | 4.13B | 5.29B | 4.04B | 2.61B | 3.81B | 2.21B | 2.79B | 2.81B | 2.49B | 2.4B | 2.65B | 2.28B | 1.96B | 1.4B | 1.54B | 973.82M | 589.89M | 556.81M | 462.99M | 324.28M | 354.1M | 267.61M | -277.88M | 331.08M | 7.01B | 5.84B |
| EBITDA Margin % | 1.78% | 1.76% | 2.2% | 3.98% | 4.74% | 4.94% | 6.85% | 6.23% | 4.58% | 7.08% | 4.05% | 5.15% | 5.8% | 6.02% | 6.13% | 7.19% | 6.73% | 6.32% | 4.81% | 6.1% | 4.55% | 4.09% | 4.25% | 3.79% | 2.88% | 3.47% | 2.53% | -2.72% | 3.36% | 87.21% | 86.02% |
| Interest Expense | 753M | 631M | 660M | 493M | 401M | 326M | 283M | 242M | 218M | 242M | 189M | 186M | 192M | 140M | 105M | 109M | 105M | 105.84M | 80.29M | 68.88M | 63.14M | 39.31M | 23.17M | 17.37M | 17.25M | 25.3M | 28.61M | 33.39M | 46.97M | 20M | 11M |
| Non-Operating Income | -486M | -631M | -660M | -493M | -401M | -326M | -283M | -242M | -218M | 694M | -189M | 84M | -192M | -140M | -151M | -109M | -267.46M | -105.84M | -183.39M | -68.88M | -63.14M | 0 | 0 | -17.37M | -17.25M | -25.3M | -28.61M | -33.39M | -46.97M | 6.88B | 5.73B |
| Pretax Income | 1.72B | 1.45B | 1.63B | 3.32B | 3.56B | 3.42B | 4.67B | 3.47B | 2.07B | 4.02B | 1.55B | 2.43B | 2.17B | 1.92B | 1.91B | 2.23B | 1.75B | 1.6B | 992.85M | 1.29B | 762.09M | 421.71M | 415.85M | 336.21M | 203.55M | 183.08M | 113.99M | -404.84M | 203.08M | 0 | 0 |
| Pretax Margin % | 1.12% | 1.12% | 1.38% | 3.12% | 3.84% | 4.09% | 6.06% | 5.34% | 3.64% | 7.47% | 2.85% | 4.48% | 4.47% | 4.65% | 4.88% | 6.07% | 5.17% | 5.17% | 3.42% | 5.1% | 3.56% | 2.92% | 3.17% | 2.75% | 1.81% | 1.8% | 1.08% | -3.96% | 2.06% | 0% | 0% |
| Income Tax | 424M | 250M | 413M | 836M | 762M | 485M | 1.31B | 763M | 391M | 1.57B | 938M | 1.16B | 1.02B | 690M | 689M | 816M | 650M | 562.09M | 345.69M | 455.62M | 274.66M | 113.23M | 135.84M | 112.47M | 67.18M | 65.91M | 23.94M | -22.42M | 74M | 97M | 6M |
| Effective Tax Rate % | 24.62% | 17.21% | 25.38% | 25.18% | 21.38% | 14.19% | 27.96% | 21.99% | 18.85% | 39.1% | 60.44% | 47.51% | 47.14% | 35.92% | 36.05% | 36.51% | 37.15% | 35.09% | 34.82% | 35.34% | 36.04% | 26.85% | 32.67% | 33.45% | 33% | 36% | 21% | 5.54% | 36.44% | - | - |
| Net Income | 1.25B | 1.19B | 1.21B | 2.49B | 2.81B | 2.93B | 3.37B | 2.71B | 1.68B | 2.45B | 614M | 1.28B | 1.15B | 1.23B | 1.22B | 1.42B | 1.1B | 1.04B | 647.15M | 833.68M | 487.42M | 308.48M | 280.01M | 223.74M | 142.75M | 117.17M | 90.05M | -382.42M | 128.96M | 173M | 12M |
| Net Margin % | 0.81% | 0.92% | 1.02% | 2.34% | 3.02% | 3.51% | 4.36% | 4.17% | 2.96% | 4.55% | 1.13% | 2.35% | 2.36% | 2.98% | 3.12% | 3.85% | 3.24% | 3.36% | 2.23% | 3.3% | 2.28% | 2.14% | 2.14% | 1.83% | 1.27% | 1.15% | 0.85% | -3.74% | 1.31% | 2.15% | 0.18% |
| Net Income Growth % | -3.56% | -1.57% | -51.51% | -11.3% | -4.33% | -12.89% | 24.38% | 60.84% | -31.25% | 298.7% | -51.88% | 11.25% | -6.82% | 0.74% | -13.88% | 29.12% | 5.71% | 60.65% | -22.37% | 71.04% | 58.01% | 10.17% | 25.15% | 56.73% | 21.83% | 30.11% | 123.55% | -396.55% | -25.46% | 1341.67% | -93.68% |
| EPS (Diluted) | 10.22 | 9.84 | 9.98 | 20.00 | 22.08 | 22.67 | 25.31 | 20.10 | 12.16 | 16.81 | 4.07 | 8.44 | 7.36 | 7.73 | 7.47 | 8.46 | 6.47 | 6.15 | 3.83 | 4.91 | 2.90 | 1.87 | 1.72 | 1.38 | 0.83 | 0.70 | 0.54 | -2.28 | 0.77 | 1.05 | 0.07 |
| EPS Growth % | -3.75% | -1.4% | -50.1% | -9.42% | -2.6% | -10.43% | 25.92% | 65.3% | -27.66% | 313.02% | -51.78% | 14.67% | -4.79% | 3.48% | -11.7% | 30.76% | 5.2% | 60.57% | -22% | 69.31% | 55.08% | 8.72% | 24.64% | 66.27% | 18.57% | 29.63% | 123.68% | -396.1% | -26.67% | 1400% | -93.97% |
| EPS (Basic) | - | 9.87 | 10.01 | 20.09 | 22.20 | 22.79 | 25.47 | 20.19 | 12.24 | 16.94 | 4.11 | 8.54 | 7.44 | 7.82 | 7.57 | 8.58 | 6.55 | 6.21 | 3.87 | 5.00 | 2.97 | 1.91 | 1.75 | 1.41 | 0.85 | 0.71 | 0.54 | -2.28 | 0.77 | 1.06 | 0.07 |
| Diluted Shares Outstanding | 121.83M | 120.83M | 120.87M | 124.44M | 127.09M | 129.4M | 133.01M | 134.73M | 138.4M | 145.58M | 150.92M | 151.14M | 155.87M | 159.15M | 163.46M | 167.83M | 169.8M | 169.07M | 168.97M | 169.82M | 168.08M | 164.96M | 162.8M | 162.13M | 171.99M | 167.39M | 166.76M | 167.73M | 167.48M | 165.84M | 165.28M |
Quick answers to the most common questions about buying HUM stock.
For fiscal year 2025, Humana Inc. (HUM) reported total revenue of $129.66B. This represents a 1810.2% increase compared to $6.79B in 1996.
Humana Inc. (HUM) is profitable, generating $1.19B in net income for the fiscal year ending 2025 with a net profit margin of 0.9%.
Humana Inc. (HUM) reported an operating income of $1.45B, resulting in an operating profit margin of 1.1%. This margin reflects the operational efficiency of the business before interest and taxes.
Humana Inc. (HUM) generated $18.85B in gross profit for the year, representing a gross profit margin of 14.5%. This demonstrates the company's core pricing power and production efficiency.
Key Metrics
Top Statement Risk
Thin margin medical cost exposure
Metrics are mathematically derived from official filings.
Revenue Growth Decelerating Into Recent Quarters
Based on Humana's reported figures, quarterly revenue rose from $29.5B in 2024Q2 to $41.2B in 2026Q3, with year-over-year growth of 26.1% in the latest quarter, though this acceleration reflects the scale of membership and premium base expansion rather than verified pricing gains.
The reported top-line expansion suggests strong Medicare Advantage membership growth and premium rate adjustments, but the data does not isolate how much derives from rate versus enrollment. Investors should monitor whether growth sustains as the benchmark environment normalizes, since high revenue growth paired with thin margins may indicate that volume is being purchased at the expense of underwriting discipline.
Combined Ratio Volatility Erodes Underwriting Cushion
According to reported figures, Humana's combined ratio ranged from 94.9% to 103.2% over the ten quarters shown, crossing 100% in both 2024Q4 and 2025Q4, indicating periods where underwriting losses required offset from other income sources.
The recurring fourth-quarter deterioration suggests seasonal utilization pressure that the company has not consistently contained through pricing or cost management. Because the loss ratio moved between roughly 82.6% and 88.3%, the spread between profit and loss periods is narrow, which may indicate limited tolerance for medical cost trend surprises.
Expense Ratio Scale Offsets Thin Claims Buffer
Based on reported quarterly data, Humana's gross margin of 14.5% and operating margin of 1.1% leave limited room for medical cost inflation, with the gap between loss ratio and combined ratio implying expense ratios near 11% to 15% of premiums.
The operating structure relies on administrative efficiency to convert premium volume into earnings, and the implied expense load appears substantial relative to the margin cushion. Investors should monitor whether CenterWell and value-based care investments reduce this expense load over time or simply add fixed costs.
Fourth-Quarter Losses Define the Earnings Cycle
As reported in financial statements, Humana posted net losses of $693.0M in 2024Q4 and $796.0M in 2025Q4, with both periods coinciding with combined ratios above 103%, suggesting a recurring year-end cost pressure pattern.
The consistency of these losses across two fiscal years points toward structural seasonal utilization rather than isolated events, which may reflect the timing of deductible resets and benefit utilization. This pattern warrants further investigation into whether reserve estimation in the final quarter has contributed to the swings.
Latest Beat Rests on Thin Foundation
Based on Humana's reported figures, the latest quarter's $162.0M net income and 1.33 EPS follow a 17.9% year-over-year EPS decline, and the claimed earnings beat is measured against a negative consensus estimate, limiting the reliability of the surprise magnitude.
Because the net margin of 0.9% is thin, a modest reversal in medical cost trend could erase the quarter's gain, and the raised-guidance narrative appears dependent on cost containment holding through upcoming periods. Investors should treat the improved tone as provisional until several consecutive quarters confirm sustained medical cost ratio improvement.